CPC Class C12Q

Disclosed are methods, systems, and devices for implementing nanoparticles to encapsulate biomolecules such as enzymes. In one aspect, a nanoparticle device includes a shell structure including an internal layer structured to enclose a hollow interior region and include one or more holes penetrating through the internal layer, and an external layer formed of a porous material around the internal layer; and an enzyme contained within the interior region of the shell structure, the enzyme having entered the shell structure through the one or more holes and incapable of passing through the external layer, in which the pores are of a size that prevents the enzyme to pass through the pores while permitting substances smaller than the pore size to pass through the pores.

The present invention provides methods, compositions, and systems for distributing single polymerase molecules into array regions. In particular, the methods, compositions, and systems of the present invention result in a distribution of single polymerase molecules into array regions at a percentage that is larger than the percentage expected to be occupied under a Poisson distribution.

Described herein are variants of alpha-hemolysin having at least one mutation selected from T12R, T12K, N17R, N17K or combinations of T12 and N17 mutations. The variants in some embodiments may further comprise H144A. The α-hemolysin variants have a decreased time to thread.

Compositions are provided that comprise a recombinant vector carrying a nucleic acid sequence encoding a fragment of CEP290 lacking all or part of its N-terminal and C-terminal inhibitory regions, under the control of regulatory sequences which express the product of said gene in a selected cell of a mammalian subject, and a pharmaceutically acceptable carrier. These and other compositions are disclosed with are useful in methods for treating a mammalian subject having a disease associated with a CEP290 mutation, such as Lebers Congenital Amaurosis.